 | | Vol. 13.27 – 22 July, 2021 |
| |
|
|
| Investigators reported the discovery of a compound, called ErSO, that activated the anticipatory unfolded protein response and induced rapid and selective necrosis of estrogen receptor α-positive breast cancer cell lines in vitro.
[Science Translational Medicine] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Engineered macrophages combined with anti-PD-L1 eliminated primary and bone metastatic breast cancer tumors, activated tumor-specific antitumor immune response, and improved overall survival with limited systemic toxicity.
[Nature Communications] |
|
|
|
| Researchers found that tumor endothelial marker 8 (TEM8) was abundantly expressed in triple-negative breast cancer and served as a marker for vasculogenic mimicry-forming breast tumor-initiating cells.
[Nature Communications] |
|
|
|
| The authors interrogated the role of YB-1 in newly arising human breast cancers as well as in established cell lines. Short-hairpin RNA-mediated knockdown of YB-1 in MDA-MB-231 cells blocked both their local tumour-forming and lung-colonising activity in immunodeficient mice.
[Cell Death & Differentiation] |
|
|
|
| Scientists performed transcriptional profiling of tumors from a Phase II clinical trial of platinum chemotherapy for advanced TNBC, revealing a gene expression signature that identified de novo chemorefractory tumors.
[Clinical Cancer Research] |
|
|
|
| The primary TNBC tumor-derived C-X-C motif chemokines 1/2/8 stimulated lung resident fibroblasts to produce C-C motif chemokines 2/7, which in turn activated cholesterol synthesis in lung-colonizing TNBC cells and induced angiogenesis at lung metastatic sites.
[Molecular Therapy] |
|
|
|
| Ligation of dexamethasone and glucocorticoid receptor on tumor cells activated the PI3K signaling pathway and upregulated serum glucocorticoid-inducible kinase 1 expression, and then increased the expression of connective tissue growth factor through Nedd4l-Smad2.
[Oncogene] |
|
|
|
| Investigators demonstrated that hsa_circ_0068631, a circular RNA generated from transferrin receptor, was upregulated in breast cancer (BC) tissues and cell lines. Knock down of hsa_circ_0068631 inhibited the proliferation and migration of BC cells in vitro and in vivo.
[Molecular Therapy-Nucleic Acids] |
|
|
|
| Scientists investigated how IL-1B from tumor cells and the microenvironment interacted to affect primary tumor growth and bone metastasis through regulation of the immune system, and whether targeting IL-1 driven changes to the immune response improved the standard of care therapy for breast cancer bone metastasis.
[npj Breast Cancer] |
|
|
|
| Researchers investigated whether and how inhibition of autophagy/mitophagy by cepharanthine affected the efficacy of chemotherapeutic agent epirubicin in TNBC cells in vitro and in vivo.
[Acta Pharmacologica Sinica] |
|
|
|
| The authors provided novel findings on mitochondrial estrogen signaling in breast cancer cells and suggested the implementation of the dynamic BH3 technique as a tool to predict acquired endocrine therapy resistance.
[Cell Death Discovery] |
|
|
|
| Scientists investigated potential correlations between electrical characteristics and biomarkers of breast cancer cells (BCCs). Changes in σ and ε of different components in suspensions of normal cells and BCCs were analyzed in the range of 200 kHz–5 MHz.
[Scientific Reports] |
|
|
|
| Researchers demonstrated that cellular FADD-like IL-1β-converting enzyme inhibitory protein (cFLIP)L was correlated with tumor necrosis factor-related apoptosis-inducing ligand-resistance and that embelin effectively downregulated cFLIPL in breast cancer cells.
[Scientific Reports] |
|
|
|
|
| The authors summarize the diverse processes underlying resistance to poly (ADP-ribose) polymerase (PARP) inhibitors and discuss the potential strategies that might overcome these mechanisms such as combinations with chemotherapies, targeting the acquired vulnerabilities associated with resistance to PARP inhibitors or suppressing genomic instability.
[Nature Reviews Clinical Oncology] |
|
|
|
| Investigators review the current progress targeting different immune checkpoints in several-lines treatment for TNBC, including programmed death-1/programmed death ligand-1 inhibitors, cytotoxic T-lymphocyte associated antigen-4 inhibitor, and other novel immunotherapeutic approaches.
[Biochimica et Biophysica Acta-Reviews On Cancer] |
|
|
|
| Scientists review the development of anticancer drugs targeting cancer-specific functional therapeutic targets, namely, maternal embryonic leucine zipper kinase, T-lymphokine-activated killer cell-originated protein kinase, and brefeldin A-inhibited guanine nucleotide-exchange protein 3, as identified through comprehensive breast cancer transcriptomics.
[Journal of Human Genetics] |
|
|
|
|
| BriaCell Therapeutics Corp. announced the open recruitment and enrollment of their collaborative clinical study with Incyte for the treatment of advanced breast cancer.
[BriaCell Therapeutics, Corp.] |
|
|
|
|
|
|
|
| | Cedars-Sinai – Los Angeles, California, United States |
|
|
|
| | University of Pittsburgh – Pittsburgh, Pennsylvania, United States |
|
|
|
| | Medical University of South Carolina – Charleston, South Carolina, United States |
|
|
|
| | Karolinska Institutet – Stockholm, Sweden |
|
|
|
| | Mayo Clinic Health System – Rochester, Minnesota, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
